- Home
- QNRX vs VRAX Comparison
QNRX vs VRAX Comparison
Compare QNRX & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- VRAX
- Stock Information
- Founded
- QNRX 2018
- VRAX 2013
- Country
- QNRX United States
- VRAX United Kingdom
- Employees
- QNRX 3
- VRAX N/A
- Industry
- QNRX Medical/Dental Instruments
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- QNRX Health Care
- VRAX Health Care
- Exchange
- QNRX Nasdaq
- VRAX Nasdaq
- Market Cap
- QNRX 4.0M
- VRAX 4.4M
- IPO Year
- QNRX N/A
- VRAX 2022
- Fundamental
- Price
- QNRX $6.97
- VRAX $0.81
- Analyst Decision
- QNRX
- VRAX Strong Buy
- Analyst Count
- QNRX 0
- VRAX 1
- Target Price
- QNRX N/A
- VRAX $3.00
- AVG Volume (30 Days)
- QNRX 4.1K
- VRAX 194.1K
- Earning Date
- QNRX 08-07-2025
- VRAX 02-05-2025
- Dividend Yield
- QNRX N/A
- VRAX N/A
- EPS Growth
- QNRX N/A
- VRAX N/A
- EPS
- QNRX N/A
- VRAX N/A
- Revenue
- QNRX N/A
- VRAX $6,331.00
- Revenue This Year
- QNRX N/A
- VRAX $217,274.83
- Revenue Next Year
- QNRX N/A
- VRAX N/A
- P/E Ratio
- QNRX N/A
- VRAX N/A
- Revenue Growth
- QNRX N/A
- VRAX N/A
- 52 Week Low
- QNRX $5.01
- VRAX $0.74
- 52 Week High
- QNRX $54.95
- VRAX $9.00
- Technical
- Relative Strength Index (RSI)
- QNRX 26.23
- VRAX 41.85
- Support Level
- QNRX $6.67
- VRAX $0.78
- Resistance Level
- QNRX $8.69
- VRAX $0.90
- Average True Range (ATR)
- QNRX 0.34
- VRAX 0.10
- MACD
- QNRX -0.22
- VRAX -0.02
- Stochastic Oscillator
- QNRX 1.08
- VRAX 13.65
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).